Featured Posts
Study
A Free Market is the Best Medicine
Introduction The pharmaceutical supply market is seeing extraordinarily high levels of innovation and consumer-benefiting evolution. The combination of a competitive market for generic drugs, rapid…
Blog
Congress considers micromanaging PBM finances
With the first reconciliation bill behind it, Congress is now looking to reform other aspects of the health care system. Pharmacy Benefit Manager (PBM)…
Blog
Free the Economy podcast: Drug costs and benefits with Sally Pipes
In this week’s episode we cover reforms to the Endangered Species Act, attacks on US tech firms, nuclear power innovation,…
Search Posts
Op-Eds
Biotech’s Antagonists
This is part 1 of a two-part series. To read part 2, please click here.<?xml:namespace prefix = o ns = “urn:schemas-microsoft-com:office:office” />…
Op-Eds
Commentary: Europe’s Ban on GMOs Is Still Firmly In Place
<?xml:namespace prefix = o ns = “urn:schemas-microsoft-com:office:office” /> There is an old saying among political veterans in <?xml:namespace prefix =…
Op-Eds
The Rocky Road to Biotech’s Success
The first Earth Day celebration, conceived by then-US Senator Gaylord Nelson, was held in 1970 as a “symbol of environmental responsibility and stewardship.” In the spirit…
Op-Eds
USDA and the Peterkin Papers
The U.S. Department of Agriculture's biotechnology regulations have been a shambles for more than fifteen years. Its compulsory case-by-case review and costly field…
Op-Eds
Frankenfood, Pro and Con
David Bowe writes in “Consumers Love Frankenfood” (editorial feature, Feb. 27) predicts that consumers will make their decision about genetically modified food…
Op-Eds
Technology for Life: How Biotech Will Save Billions from Starvation
Full article available in pdf format Today, most people around the world have access to a greater variety of nutritious…